Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director | June 06, 2025 | June 10, 2025 |
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | Director | June 25, 2026 | June 29, 2026 |
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Director | October 18, 2023 | November 03, 2023 |
| DELCATH SYSTEMS, INC.DCTH · Entity 5387 | Director | May 13, 2026 | May 14, 2026 |
| JUNIPER PHARMACEUTICALS INCJNP · Entity 164322 | Chief Medical Officer | March 03, 2017 | March 07, 2017 |
| Old Ayala, IncADXS · Entity 108681 | Director | October 18, 2023 | November 01, 2023 |
| POINT Biopharma Global Inc.PNT · Entity 95793 | Director | June 13, 2023 | June 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date June 06, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.83 · Expires 2035-06-06 | Direct | 31,500 |
Reported balance
After 2025-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-06 · Grant · Acquired 31,500 · Balance 31,500 F1: The options vest 100% on the earlier of June 6, 2026 or the date immediately prior to the Issuer's 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on the earlier of June 6, 2026 or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
Aligos Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2036-06-25 | Direct | 5,860 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 5,860 · Balance 5,860 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
Ayala Pharmaceuticals, Inc.
Report date October 18, 2023 · Filed November 03, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
This filing explicitly reported no securities owned.
DELCATH SYSTEMS, INC.
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 | Direct | 22,500 |
Reported balance
After 2026-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 22,500 · Balance 22,500 F1: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service.
JUNIPER PHARMACEUTICALS INC
Report date March 03, 2017 · Filed March 07, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,500 |
Reported balance
After 2017-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-03-03 · Grant · Acquired 15,500 · Balance 15,500 F1: This Restricted Stock Unit Award shall vest 25% on each anniversary of the date of grant over 4 years. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.15 · Expires 2024-03-03 | Direct | 74,900 |
Reported balance
After 2017-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-03 · Grant · Acquired 74,900 · Balance 74,900 F2: The option will be exercisable in 25% increments of the shares on each annual anniversary of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This Restricted Stock Unit Award shall vest 25% on each anniversary of the date of grant over 4 years.
F2: The option will be exercisable in 25% increments of the shares on each annual anniversary of the date of the grant.
Old Ayala, Inc
Report date October 18, 2023 · Filed November 01, 2023
This filing explicitly reported no securities owned.
POINT Biopharma Global Inc.
Report date June 13, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.08 · Expires 2029-06-13 | Direct | 80,503 |
Reported balance
After 2023-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 80,503 · Balance 80,503 F1: The option will vest 100% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest 100% on the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kura Oncology, Inc.
Report date August 24, 2020 · Filed December 15, 2020
Section 16 reporting ended · disclosed 2020-12-15. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:37 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 5,860 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001610717-26-000303 · form4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,860 Underlying: Common Stock · 5,860 shares Expires 2036-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| May 13, 2026 Filed May 14, 2026 21:45 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001629627-26-000003 · form4-05142026_090552.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires not disclosed F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. F1 · derivative.expiration_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 20:29 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 5,860 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001610717-25-000254 · form4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,860 Underlying: Common Stock · 5,860 shares Expires 2035-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:51 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0000950170-25-084420 · ownership.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2035-06-06 F1 · derivative.exercise_date: The options vest 100% on the earlier of June 6, 2026 or the date immediately prior to the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:10 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $16.05 | $0.00 |
DisclosureSEC source: 0001415889-25-013612 · form4-05192025_040503.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires not disclosed F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 15, 2025 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. F1 · derivative.expiration_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 15, 2025 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:07 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001610717-24-000369 · form4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:28 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0001415889-24-014671 · form4-05282024_080506.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires not disclosed F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 23, 2024 and monthly thereafter for so long as the reporting person remains a director of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. F1 · derivative.expiration_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 23, 2024 and monthly thereafter for so long as the reporting person remains a director of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:29 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 8,823 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000094 · form4.xml · derivative · entry 2 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,823 Underlying: Common Stock · 8,823 shares Expires 2031-11-16 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on November 16, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:29 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0001610717-24-000094 · form4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-11-16 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on November 16, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share. Read SEC document |
| January 22, 2024 Filed Jan 29, 2024 19:07 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-24-002333 · doc4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2034-01-22 F1 · derivative.exercise_date: The options vest 100% on the earlier of 18 months from the grant date or the date immediately prior to the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| July 20, 2023 Filed Jul 22, 2023 01:06 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000217 · form4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 22:15 UTC | POINT Biopharma Global Inc. PNT · Entity 95793 | GrantStock Option (Right to Buy) · Derivative | 80,503 | $0.00 Strike: $10.08 | $0.00 |
DisclosureSEC source: 0001104659-23-071303 · tm2318760-1_4seq1.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,503 Underlying: Common Stock · 80,503 shares Expires 2029-06-13 F1 · derivative.exercise_date: The option will vest 100% on the first anniversary of the grant date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:15 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035793 · doc4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2033-06-07 F1 · derivative.exercise_date: The options vest 100% on the earlier of June 7, 2024 or the date immediately prior to the Issuer's next annual meeting of stockholders. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:11 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-22-013387 · doc1.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 20:10 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 4,400 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001209191-22-033135 · doc4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2032-05-31 F1 · derivative.exercise_date: The options vest 100% on the earlier of May 31, 2023 or the date immediately prior to the Issuer's next annual meeting of stockholders. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:38 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0001567619-21-020770 · doc1.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-11-16 F1 · derivative.exercise_date: 1/36th of the total number of shares vest in thirty-six (36) successive and equal monthly installments measured from November 16, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:56 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 5,650 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-21-021393 · doc4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,650 Underlying: Common Stock · 5,650 shares Expires 2031-03-15 F1 · derivative.exercise_date: The options vest in monthly installments over 36 months commencing one month from March 15, 2021. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $12.22 | $0.00 |
DisclosureSEC source: 0001209191-20-008730 · doc4.xml · derivative · entry 2 Martell Bridget A · CIK 0001629627 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-09 F2 · derivative.exercise_date: 1/4th of the shares vest on the one year anniversary of the date of grant, and 1/48th of the shares vest in 36 monthly installments thereafter. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $12.22 | $0.00 |
DisclosureSEC source: 0001209191-20-008730 · doc4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 17:01 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantEmployee Stock Option (Right to Buy) · Derivative | 74,900 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001209191-17-018801 · doc4.xml · derivative · entry 2 Martell Bridget A · CIK 0001629627 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,900 Underlying: Common Stock; $0.01 par value per share · 74,900 shares Expires 2024-03-03 F2 · derivative.exercise_date: The option will be exercisable in 25% increments of the shares on each annual anniversary of the date of the grant. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 17:01 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-018801 · doc4.xml · nonDerivative · entry 1 Martell Bridget A · CIK 0001629627 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 F1 · security: This Restricted Stock Unit Award shall vest 25% on each anniversary of the date of grant over 4 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.